Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s program

On June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion based on milestones.

Bial disclosed that it is ending development of a Parkinson’s disease drug after the program failed to meet its objectives.

The briefing also listed activity from several other biotech firms, but no further details were provided.